Patient-self-adaptive system for detection, recording and alert to caregivers of night-time seizures, linked to private cloud platform for patient tracking and big data exploitation.

Projektinformationen

SEIZSAFE

ID Finanzhilfevereinbarung: 726947

DOI 10.3030/726947

Abgeschlossenes Projekt

EK-Unterschriftsdatum 4 Mai 2016

Startdatum 1 Juni 2016

Enddatum 28 Februar 2019

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 856 375,00

EU-Beitrag € 599 462,50

Koordiniert durch

ENCORE LAB SL
Spain

Ziel

Approximately 50 million people worldwide have epilepsy, an illness characterized by recurrent seizures. The estimated proportion of the general population with active epilepsy is between 4 and 10 per 1000 people. Globally, an estimated 2.4 million people are diagnosed with epilepsy each year.
When patients suffer generalized convulsions there is a risk for them of being injured or having a cardiac arrest. Caregivers (usually patients’ relatives) reduce this risk by being alert and applying techniques such as holding the patients, putting them in a certain stance or providing them with the prescribed drugs. The problem worsens when seizures occur at night-time.
Caregivers usually sleep in the same bedroom as patients and cannot rest due to the constant concern, leading to inconveniences such as loss of privacy, bad resting and higher risk for patients. This project aims to improve the lives of people affected by epilepsy, both patients and caregivers, providing them with an effective and unobtrusive device to monitor patients and alert caregivers during night-time seizures.
This project consists on a patient-self-daptive system to detect, video-record and alert caregivers of night-time seizures, linked to a private cloud platform for medical tracking of patients and big data exploitation. The main innovative characteristics of SEIZSAFE are:
• Patient-self-adaptive and self-learning algorithm for seizure detection
• Camera and cloud platform for doctors
• Reduced-cost technology
• Medical validation
The present project aims to expand SEIZSAFE in the European market. Considering a global market size of 1.2M epilepsy patients suffering night-time seizures, ENCORE foresees the uptake of 6.5% of the market in 5 years, which means 80,000 users by the end of 2022.

Wissenschaftliches Gebiet

• humanities › languages and literature › general language studies
• medical and health sciences › health sciences › health care services › eHealth
• medical and health sciences › basic medicine › neurology › epilepsy
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › computer and information sciences › data science › big data

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.4. - Active ageing and self-management of health
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.1.6. - Health care provision and integrated care

Thema/Themen

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

ENCORE LAB SL

• Netto-EU-Beitrag: € 599 462,50
• Adresse: AVDA ZARAGOZA 18, 1º OF. 2 ; Logrono ; Spanien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Noreste › La Rioja › La Rioja
• Region: Noreste › La Rioja › La Rioja
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 856 375,00